Private Equity in Ophthalmology

The role of private equity (PE) in ophthalmology has shifted the practice landscape during the past 10 years. While proponents of PE investment tout the benefit of extra access to capital and resources, critics fear that these partnerships lead to a loss of autonomy and potential risk to patient care. In this episode, Drs. Dagny Zhu, Omar Shakir, and Ravi Parikh review the current published data about PE in ophthalmology and share their personal perspectives on its real-world impact on clinical practice.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

CME Information

Release: February 9, 2023; expires February 9, 2026

Disclosures: 
Planner/Faculty: Dr. Pouw reports no relevant financial disclosures.
Faculty: Drs. Parikh, Shakir, and Zhu report no relevant financial disclosures.
Review Panel: Dr. Mazeyar Saboori receives consulting and lecture fees from Aerie Pharmaceuticals. The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MD, MPH; Annie Moreau, MD; and Allison Umfress, MD.

Learning Objective: Upon completion of this episode, the listener should be able to describe the current published data about private equity in ophthalmology and its potential impact on clinical practice.

Audience: This activity is intended for comprehensive ophthalmologists.

Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.